-
Loading metrics
Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab
- R. J. S. D. Heine,
- F. W. Thielen,
- R. H. J. Mathijssen,
- R. W. F. van Leeuwen,
- M. G. Franken,
- C. A. Uyl-de Groot
x
- Published: February 1, 2024
- https://doi.org/10.1371/journal.pone.0293264